n Cardiovascular Journal of South Africa - Multi-centre trial of aprotinin highlights increased safety with higher dose : drug trends in cardiology

Volume 13, Issue 2
  • ISSN : 1680-0745



Extracted from text ... High-dose aprotinin reduces transfusion requirements in patients undergoing coronary artery bypass grafting, but the safety and effectiveness of smaller doses is unclear. Furthermore, patient selection criteria for optimal use of the drug are not well defined. Seven hundred and four first-time coronary artery bypass grafting patients were randomised to receive one of three doses of aprotinin (high, low and pump-prime only) or placebo. The patients were stratified according to risk of excessive bleeding. All three aprotinin doses were highly effective in reducing bleeding and transfusion requirements.1 Consistent efficacy was not, however, demonstrated in the subgroup of patients at low risk ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error